Tag Archives: Coronavirus

Delta variant doubles risk of hospitalization; Novavax vaccine highly effective in large trial

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Delta variant doubles risk of COVID-19 hospitalization

The delta variant of the coronavirus first identified in India may double the risk of hospitalization among COVID-19 patients, compared with the alpha variant first discovered in the UK, a study from Scotland suggests. Researchers looked at 19,543 COVID-19 cases and 377 hospitalizations among 5.4 million people, including 7,723 cases and 134 hospitalizations in patients with the delta variant, who tended to be younger and more affluent. The risk of COVID-19 hospital admission was about double with the delta variant compared to the alpha variant, with the risk particularly increased in those with five or more medical conditions known to contribute to more severe disease, the researchers reported on Monday in The Lancet. They found that two doses of the vaccines from Pfizer and BioNTech and from AstraZeneca still provide strong protection, although not as strong as the protection provided against the alpha variant. Two weeks after the second dose, the Pfizer/BioNTech vaccine was found to provide 79% protection against infection from the delta variant, compared to 92% against the alpha variant. With AstraZeneca’s vaccine, there was 60% protection against delta compared with 73% for alpha. Because this was an observational study, more research is needed to confirm the findings, the research team said.

Novavax vaccine highly effective in North American trial

Novavax Inc on Monday said its COVID-19 vaccine was more than 90% effective, including against a variety of concerning coronavirus variants, in a large, late-stage clinical trial, providing another potential weapon against the disease once approved for use. In the trial involving nearly 30,000 volunteers in the United States and Mexico, the two-shot vaccine was 100% effective in preventing infection by the original version of the coronavirus, the company said. It was more than 93% effective against the predominant variants of the virus that have been of concern among scientists and public health officials. The alpha variant first identified in the UK was the predominant variant in the United States while the trial was being conducted, the company said. The vaccine was 91% effective among volunteers at high risk of severe infection and 100% effective in preventing moderate and severe cases of COVID-19. Novavax said the vaccine was generally well tolerated, with side effects similar to those seen with existing COVID-19 vaccines. The Novavax COVID-19 shot is a more conventional type of vaccine than those currently available. It contains an actual version of the virus’ spike protein that cannot cause disease but can trigger the immune system directly. The company said the results put it on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021.

Tetanus, diphtheria boosters tied to less severe COVID-19

Older individuals who have gotten a diphtheria or tetanus vaccine booster shot in the last 10 years may be at lower risk for severe COVID-19, a new study suggests. Using a large UK registry, researchers looked back at 10 years of immunization records from 103,409 participants with an average age of 71. They saw a trend toward a lower risk of a positive COVID-19 test in people who had gotten a tetanus or diphtheria booster shot during the study period, although the difference was small and might have been due to chance. There was, however, a statistically significant association between the booster shots and the odds of severe COVID-19. After accounting for age, sex, underlying respiratory diseases, and socioeconomic status, the odds of developing severe COVID-19 were 64% lower in people who had gotten a diphtheria booster and 50% lower in recipients of tetanus booster, according to a report posted on medRxiv on Saturday ahead of peer review. The study does not prove cause and effect. If there is some effect of the boosters, it might be that they protect against severe COVID-19 symptoms by stimulating the immune system, the authors suggest. “The possibility that these vaccinations may influence the severity of COVID-19 warrants follow-up investigations,” they conclude.

(Reporting by Nancy Lapid, Carl O’Donnell and Alistair Smout; Editing by Bill Berkrot)

U.S. COVID-19 deaths cross painful 600,000 milestone as country reopens

By Sharon Bernstein

(Reuters) – The United States has now lost over 600,000 mothers, fathers, children, siblings and friends to COVID-19, a painful reminder that death, sickness and grief continue even as the country begins to return to something resembling pre-pandemic normal.

A bride forced by the pandemic to have a Zoom wedding is planning a lavish in-person anniversary celebration this summer, but all of the guests must attest they are vaccinated.

A Houston artist, still deep in grief, is working on a collage of images of people who died in her community. Others crowd theaters and bars, saying it is time to move on.

“There will be no tears – not even happy tears,” said Ali Whitman, who will celebrate her first wedding anniversary in August by donning her gown and partying with 240 vaccinated friends and family members in New Hampshire.

COVID-19 nearly killed her mother. She spent her wedding day last year with 13 people in person while an aunt conducted the ceremony via Zoom.

“I would be remiss not to address how awful and how terrible the past year has been, but also the gratitude that I can be in a singular place with all the people in my life who mean so much to me,” said Whitman, 30.

The United States passed 600,000 COVID-19 deaths on Monday, about 15% of the world’s total coronavirus fatalities of around 4 million, a Reuters tally shows.

The rate of severe illness and death has dropped dramatically as more Americans have become vaccinated, creating something of a psychological whiplash that plagues the millions whose lives have been touched by the disease. Many are eager to emerge from more than a year of sickness and lockdown, yet they still suffer – from grief, lingering symptoms, economic trauma or the isolation of lockdown.

“We’ve all lived through this awful time, and all of us have been affected one way or another,” said Erika Stein, who has suffered from migraines, fatigue and cognitive issues since contracting COVID-19 last fall. “My world flipped upside down in the last year and a half – and that’s been hard.”

Stein, 34, was active and fit, working as a marketing executive and fitness instructor in Virginia outside Washington, D.C., before the initial illness and related syndrome known as long-COVID ravaged her life.

Like many, she has mixed feelings about how quickly cities and states have moved to lift pandemic restrictions and re-open.

‘FOR MY FAMILY, THERE IS NO NORMAL’

In New York, social worker Shyvonne Noboa still cries talking about the disease that ravaged her family, infecting 14 out of 17 relatives and killing her beloved grandfather, who died alone in a hospital where they could not visit him.

She breaks down when she goes to Target and sees the well-stocked aisles, recalling the pandemic’s depths, when she could not find hand sanitizer to protect her family.

“New York City is going back to quote-unquote ‘normal’ and opening up, but I can assure you that for my family there is no normal,” said Noboa, who lives in Queens, an early epicenter of the U.S. outbreak. She is vaccinated but still wears a mask when she is out, and plans to continue doing so in the near future.

In Houston, artist Joni Zavitsanos started looking up obituaries of people in Southeast Texas who had died in the pandemic’s early days, reading their stories and creating mixed-media memorials displaying their names and photographs. Around each person she painted a halo using gold leaf, an homage to the Byzantine art of the Greek Orthodox church she attends.

Zavitsanos has now created about 575 images, and plans to keep going, making as many as she can, each portrait on an eight-by-eight-inch piece of wood to be mounted together to form an installation. Her brother and three adult children contracted COVID-19 and recovered. A very close friend nearly died and is still struggling with rehabilitation.

Chris Kocher, who founded the support and advocacy group COVID Survivors for Change, urged sympathy and support for people who are still grieving.

“We’re being given this false choice where you can open up and celebrate, or you need to be locked down in grief,” he said. “Let’s be thankful that people are getting vaccinated, but let’s also acknowledge that going back to normal is not an option for millions of Americans.”

One way to acknowledge the toll that COVID-19 has taken is to incorporate the color yellow into celebrations and gatherings, or display a yellow heart, which for some has become a symbol of those lost to the disease, he said.

The bittersweet mix of grief at the pandemic’s toll with relief brought by its ebb was clear at Chicago’s O’Hare airport on Thursday, where Stephanie Aviles and her family waited for a cousin to arrive from Puerto Rico.

Aviles, 23, lost two close friends to the virus, and her father nearly died. And yet, here she was, greeting family she had not been able to see for 15 months as the pandemic raged.

“I’m grateful, but it’s a lot,” she said. “It’s a strange feeling to be normal again.”

(Reporting by Sharon Bernstein; Additional reporting by Brendan O’Brien; Editing by Bill Berkrot)

Novavax COVID-19 vaccine more than 90% effective in U.S. trial

By Carl O’Donnell

(Reuters) – Novavax Inc on Monday reported late-stage data from its U.S.-based clinical trial showing its vaccine is more than 90% effective against COVID-19 across a variety of variants of the virus.

The study of nearly 30,000 volunteers in the United States and Mexico puts Novavax on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021, the company said.

Novavax’s protein-based COVID-19 vaccine candidate was more than 93% effective against the predominant variants of COVID-19 that have been of concern among scientists and public health officials, Novavax said.

Protein-based vaccines are a conventional approach that use purified pieces of the virus to spur an immune response and vaccines again whooping cough and shingles employ this approach.

During the trial, the B.1.1.7 variant first discovered in the United Kingdom became the most common variant in the United States, it said.

Novavax also detected variants of COVID-19 first found in Brazil, South Africa and India among its trial participants, Novavax’s head of research and development, Dr. Gregory Glenn, told Reuters.

The vaccine was 91% effective among volunteers at high risk of severe infection and 100% effective in preventing moderate and severe cases of COVID-19. It was roughly 70% effective against COVID-19 variants that Novavax was unable to identify, Glenn said.

“Practically speaking, it’s very important that the vaccine can protect against a virus that is wildly swinging around” in terms of new variants, Glenn said.

Novavax said the vaccine was generally well tolerated among participants. Side effects included headache, fatigue and muscle pain and were generally mild. A small number of participants experienced side effects described as severe.

Novavax remains on track to produce 100 million doses per month by the end of the third quarter of 2021 and 150 million doses per month in the fourth quarter of 2021, the company said.

The Maryland-based company has repeatedly pushed back production forecasts and has struggled to access raw materials and equipment needed to make its vaccine.

However, in a May investor call, Chief Executive Stanley Erck said major manufacturing hurdles have been cleared and that all of its facilities can now produce COVID-19 vaccine at commercial scale.

Erck said that Novavax has begun its regulatory filing in India in partnership with the Serum Institute of India, which is contracted to make Novavax shots.

Erck said his understanding is that SII is no longer constrained by raw materials shortages.

SII had said in March that U.S. restrictions on exports of supplies used for vaccines were limiting its ability to scale up production.

(Reporting by Carl O’Donnell; Editing by Lisa Shumaker)

Vaccines effective vs variants despite diminished antibodies; kids may be as contagious as adults

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Vaccines protect against variants despite diminished antibodies

The one-dose Johnson & Johnson COVID-19 vaccine and the two-dose vaccine from Pfizer and BioNTech appear to protect against worrisome coronavirus variants despite diminished levels of antibodies that can neutralize the newer versions of the virus, two studies in the journal Nature suggest. The authors of both studies said other immune responses may be compensating. In one study, published on Wednesday, researchers experimented with blood from people who had received the J&J vaccine two months earlier. Compared to their levels of neutralizing antibodies against the virus that was circulating early in the pandemic, levels of neutralizing antibodies against variants first identified in the UK, South Africa, Brazil and California were about three-fold lower. However, the researchers observed other “robust” immune activity and cells whose responses against the variants were undiminished. In clinical trials, the researchers noted, the J&J vaccine protected against symptomatic COVID-19 in South Africa and in Brazil, where most cases were caused by the variants. Its effectiveness in these regions raises the possibility that these other immune responses may be contributing to protection, coauthor Dr. Dan Barouch of Beth Israel-Deaconess Medical Center in Boston, said in a statement. In a separate study using blood from recipients of the Pfizer/BioNTech shots, levels of antibodies that could neutralize concerning variants first identified in India and Nigeria were lower compared to an earlier version of the virus, researchers reported on Thursday. Still, they reported “robust neutralization” of all tested variants. Neutralizing antibodies, the researchers said, do not reflect all potentially protective vaccine responses.

Children with COVID-19 may be as contagious as adults

In a community-based study of COVID-19 patients who were not hospitalized, U.S. researchers found that children and adults with symptoms had similar viral loads, which suggests children can be just as contagious as grownups. “There has been a lot of debate around school openings and about whether children could transmit the virus and we thought this study could help answer some of these questions,” said Dr. Helen Chu of the University of Washington, who coauthored a report published on Friday in JAMA Pediatrics. Her team looked at 123 children and 432 adults with COVID-19 and found that nearly all of the adults had symptoms, compared to about two-thirds of the children. “Overall, people with symptoms had higher virus levels than people without symptoms,” Chu said. “However, when you looked within these groups – those with symptoms or those without – viral load was the same whether you were a child or an adult.” She noted that swab tests were only done once, so researchers cannot be sure they took place when patients’ viral loads were highest. But overall, she said, children in the community with SARS-CoV-2 infection can have virus levels similar to adults and can transmit it to others.

Oral booster vaccine shows promise in animal tests

An experimental “booster” vaccine against COVID-19 that is taken by mouth has yielded promising early results in studies in rats, Israeli researchers said. The oral vaccine, MigVax-101, targets multiple sites on the coronavirus. Along with the spike protein on the surface of the virus, which is the target of currently available vaccines, the oral vaccine also targets two sites on the virus shell, which encapsulates its genetic material. In laboratory experiments, rats that had received two doses of vaccines that targeted the spike protein were given the oral booster. “These rats developed a much higher level of antibodies for neutralizing the disease than did control group rats that received a placebo or a third injection of the (original) vaccine,” said David Zigdon of MIGAL Galilee Research Institute Ltd, who coauthored a report posted on Wednesday on bioRxiv ahead of peer review. If it is proven safe for humans, an oral vaccine might trigger strong immune responses in the mucosal surfaces of the mouth and upper respiratory tract, which would in turn help block viral entry, the researchers speculated. An oral vaccine could be particularly useful in developing countries because it would avoid the need for distribution of needles and could be self-administered.

(Reporting by Nancy Lapid and Christine Soares; Editing by Bill Berkrot)

Coronavirus wave takes Haiti, yet to begin vaccinations, by surprise

By Andre Paultre and Sarah Marsh

PORT-AU-PRINCE (Reuters) – For more than a year, Haiti escaped the worst ravages of the COVID-19 pandemic, reporting few cases and fatalities – a rare break for the poorest country in the Americas, which has so often been beset by misfortune.

COVID-19 treatment centers closed for lack of patients, Haitians resumed life as normal, and the government hesitated to even accept its allotment of free AstraZeneca vaccines through the U.N.-backed COVAX mechanism due to safety and logistical concerns.

Now, though, as some countries are already moving into a post-pandemic phase thanks to vaccination campaigns, Haiti is grappling with its first serious outbreak.

And it is one of only a handful of countries worldwide that has yet to administer a single shot of coronavirus vaccine.

Last month, infections and fatalities rose more than fivefold following the arrival of new variants, in what the Pan American Health Organization (PAHO) called a “cautionary tale in just how quickly things can change with this virus.”

Officially, Haiti had recorded 15,895 infections and 333 deaths from COVID-19 as of June 5 among its 11 million people – relatively low case numbers compared to elsewhere in Latin America and the Caribbean.

Yet data is limited due to low testing rates and doctors say the real numbers are likely much higher. Every day comes news of deaths from COVID-19 of well-known figures, like a former senator or the head of the pension agency.

And the upwards trend could prove “catastrophic,” according to Laure Adrien, General Director of Haiti’s Health Ministry.

Poor sanitation means disease can spread fast in Haiti. Its slums are densely packed, and its already overwhelmed and shambolic healthcare system is dependent on fickle donations.

Last week, two of the main hospitals treating COVID-19 patients in capital Port-au-Prince announced they were saturated.

“We are overwhelmed with patients,” said Marc Edson Augustin, medical director of St. Luke Hospital.

Jean ‘Bill’ Pape, a top Haitian infectious disease expert, said the country was now not as prepared as it had been.

“We need to reopen new centers to increase the number of dedicated COVID beds,” said Pape.

The new wave also comes amid surging gang violence that is hampering the provision of what little healthcare is available.

The St. Luke hospital warned on Monday it may have to close its COVID-19 unit altogether as violence was making it hard to stock up on oxygen at the production site in the Cite Soleil slum.

Already in February Doctors Without Borders (MSF) shut all but the emergency department at the hospital in Cite Soleil where it last year treated COVID-19 patients.

Wealthier Haitians are paying to be medevaced to Florida or the Dominican Republic.

NOT A PRIORITY

Haitian doctors largely credited their country’s apparent resilience to the coronavirus last year to its relatively young population. Around half of Haitians are under 25 years old.

Many locals dismissed the virus as not a big deal or even doubted its existence. Its importance faded amid a growing humanitarian crisis in the wake of political unrest and extreme weather associated with climate change.

So when reports emerged last month of the arrival of the new variants first identified in Britain and Brazil and an uptick in cases, reaction was initially subdued.

Authorities mandated renewed precautions like masks in public spaces, instituted an overnight curfew, and suspended year-end graduation ceremonies. President Jovenel Moise urged Haitians to drink medicinal tea to ward off the virus, an unproven remedy.

Yet many Haitians continued life as usual, with authorities unwilling or unable to enforce measures. One mayor of a Port-au-Prince district last week staged a music concert attended by thousands not wearing masks.

Pressure is building, though. PAHO Director Carissa Etienne said last week there was “no time to waste” as additional health capacity and preventive measures to curb transmission would be “decisive.”

Businesses are starting to require Haitians to only enter wearing masks and new COVID-19 treatment centers are opening.

“We have to open new structures to take more patients with respiratory difficulties to avoid a catastrophe,” said Ronald Laroche, a doctor who runs a network of low-cost health centers and hospitals, and opened a COVID-19 center this week.

On Monday, the electoral council postponed a referendum on a new constitution that had been scheduled for the end of June.

And next week, Haiti should receive its first batch – 130,000 doses – of COVID-19 vaccines through the World Health Organization’s COVAX vaccination scheme.

Doctors say the challenge now will be convincing Haitians to actually have the vaccine.

Ronald Jean, 38, a restaurant manager in Port-au-Prince, said he was for the first time afraid of the virus.

But “first the authorities should take the vaccine on television, we’ll see how they do,” he said. “And then I will decide whether or not to take it.”

(Reporting by Andre Paultre and Valerie Baeriswyl in Port-au-Prince and Sarah Marsh in Havana; Additional reporting by Anthony Boadle in Sao Paolo; Editing by Rosalba O’Brien)

Nepal worries future coronavirus wave will hit children hard

By Gopal Sharma

KATHMANDU (Reuters) – Nepal asked its hospitals on Friday to reserve beds for children for fear another surge in coronavirus infections will hit them hard, something officials in neighboring India are also preparing for.

The move came as the government approved for emergency use the COVID-19 vaccine made by Sinovac Biotech of China.

Prime Minister K.P. Sharma Oli’s government has been criticized by experts for its handling of the ongoing second wave in Nepal, which has led to an acute shortage of oxygen, hospital beds and medicines.

“Hospitals and medical institutions must set aside at least 20% of beds for children, who are likely to suffer the most in the potential third and fourth waves of coronavirus,” the Ministry of Health and Population said in a statement.

“Hospitals must also ensure the availability of enough oxygen.”

Daily infections in the Himalayan nation are hovering around 5,000 after hitting a peak of more than 9,000 in early May. Nepal had reported fewer than 100 daily cases in March. It has reported 581,560 infections in total and 7,731 deaths.

Donors have rushed aid including oxygen, protective gear, drugs and face masks to the country, which is also struggling to secure vaccines after neighboring India stopped exports to meet its local demand.

Santosh K.C., a spokesman for the Department of Drug Administration, said “conditional permission for the emergency use” had been given for the coronavirus vaccine (Corona Vac) made by Sinovac Biotech of China, the fifth shot to be approved by Nepal.

Earlier it had approved two Indian-made vaccines – AstraZeneca’s and COVAXIN – China’s Shinopharm and Russia’s Sputnik V for emergency use in the Himalayan nation.

Nepal has provided at least 3.1 million vaccinations to its people so far.

(Reporting by Gopal Sharma; editing by Jonathan Oatis)

Virus does not threaten U.S. blood supply; high vitamin D levels do not protect against COVID-19

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Coronavirus does not threaten U.S. blood supply

Current guidelines for screening U.S. blood donors for symptoms of COVID-19 and for a history of recent infections are effectively protecting the blood supply from contamination with the new coronavirus, researchers say. In a study conducted for the National Institutes of Health, researchers tested nearly 18,000 “mini pools” of blood samples – that is, blood samples pooled from total of roughly 258,000 donors from across the country. Only three mini pools contained genetic material from the virus, according to a report published in the journal Transfusion. In all three, the viral levels were low. In the one mini pool that could be tested for infectivity, the virus material was noninfectious, the researchers said. “Other studies have shown that in rare cases where a blood sample tested positive, transmission by blood transfusion has not occurred,” coauthor Sonia Bakkour of the University of California, San Francisco, said in a statement. “Therefore, it appears safe to receive blood as a transfusion recipient and to keep donating blood, without fear of transmitting COVID-19 as long as current screenings are used.”

High vitamin D levels do not protect against COVID-19

Low levels of vitamin D have been tied to higher risks for COVID-19 and more severe illness, although no studies have proved that vitamin D deficiency is actually to blame. A study published on Tuesday in PLoS Medicine suggests that boosting vitamin D levels with supplements would not help. Researchers studied more than 1.2 million people of European ancestry from 11 countries, some of whom had genetic variants that result in naturally higher levels of vitamin D. People with these variants did not have a lower risk for coronavirus infection, hospitalization, or severe COVID-19, the researchers reported. Their results suggest that boosting vitamin D levels in deficient people probably would not help combat the coronavirus, and they do not believe randomized trials testing vitamin D supplementation would be worthwhile. Other experts, however, would still like to see such trials, especially in people of African and other non-European ancestries.

Immune system workaround helps blood cancer patients with COVID-19

In blood cancer patients who lack antibody-producing cells, other immune cells can compensate to help fight the coronavirus, new research shows. People with blood cancers – such as leukemia, lymphoma, and myeloma – often lack antibody-making immune cells called B cells, particularly after treatment with certain medications. Without enough B cells and antibodies, they are at risk for severe COVID-19. But other immune cells, called T cells, learn to recognize and attack the virus, according to a report published in Nature Medicine. Blood cancer patients in the study were more likely to die from COVID-19 than patients with solid tumors or without cancer. But among the blood cancer patients, those with higher levels of CD8 T cells were more than three times more likely to survive than those with lower levels of CD8 T cells. The authors speculate that CD8 T cell responses to COVID-19 vaccines might protect blood cancer patients even if they do not have typical antibody responses. “This work can help us advise patients while we wait for more vaccine specific studies,” said co-author Dr. Erin Bange of the University of Pennsylvania in a statement. While patients’ vaccine response “likely will not be as robust as their friends/family who don’t have blood cancers, it is still … potentially lifesaving,” Bange added.

In some long COVID cases, air gets trapped in lungs

Some COVID-19 survivors with persistent breathing symptoms have a condition called “air trapping,” in which inhaled air gets stuck in the small airways of the lung and cannot be exhaled. Researchers studied 100 COVID-19 survivors who were still having respiratory problems, like coughs and shortness of breath, an average of more than two months after their diagnosis. Overall, 33 had been hospitalized, including 16 who had needed intensive care. The amount of lung area showing so-called ground-glass opacities on imaging studies – a typical sign of lung damage from COVID-19 – was higher in the hospitalized group than in those with milder disease, and it was even higher in patients who had required intensive care. COVID-19 severity made little difference in the average percentage of lung affected by air trapping, however. It was 25.4% in patients not hospitalized, 34.5% in those who were hospitalized without intensive care, and 27.2% in patients who had been critically ill. By comparison, that proportion was 7.3% in a group of healthy volunteers. The air trapping was largely confined to patients’ narrowest airway passages, according to a report posted on Saturday on medRxiv ahead of peer review. “The long-term consequences” of these patients’ small airways disease “are not known,” the authors said.

(Reporting by Nancy Lapid; Editing by Bill Berkrot)

Factbox: Latest on the worldwide spread of the coronavirus

(Reuters) – The head of the World Health Organization has called for launching negotiations this year on an international treaty to boost pandemic preparedness, as part of sweeping reforms envisioned by member states.

EUROPE

* Germany’s Robert Koch Institute (RKI) for infectious disease is to reduce the coronavirus risk level for the country to “high” from “very high” as the situation improves, Health Minister Jens Spahn said.

* Spain is considering easing rules on wearing face masks outdoors, as early as in mid-June.

AMERICAS

* With half the country at least partially protected against the coronavirus, Americans escaped their pandemic doldrums over the Memorial Day holiday weekend.

ASIA-PACIFIC

* South Korea closed its first phase of reservations for Johnson and Johnson vaccines as military personnel signed up for all 800,000 shots on offer, the government said.

* A shipment of coronavirus vaccines to North Korea via the global COVAX sharing program that was expected for late May has been delayed again amid protracted consultations, South Korea’s Unification Ministry said.

* Australia’s Victoria state authorities said it was still unclear whether a snap one-week lockdown to contain a fresh COVID-19 outbreak would end as planned on Thursday night, as the state grapples with a growing virus outbreak.

* Japan plans to start vaccination at workplaces and universities on June 21 to speed up the country’s inoculation drive.

MIDDLE EAST AND AFRICA

* Dubai, the second-largest member of the United Arab Emirates federation, has started offering the Pfizer-BioNTech vaccine to 12-15 year old’s, the government media office said on Twitter.

* Turkey further eased measures including partially lifting a weekend lockdown and opening restaurants to a limited number of guests.

MEDICAL DEVELOPMENTS

* A Wuhan-based affiliate of China’s Sinopharm said the start of operations at a new factory will raise the annual production capacity of its COVID-19 vaccine to at least 1 billion doses.

* A deal on an intellectual property waiver for COVID-19 vaccines at the World Trade Organization was no closer to acceptance on Monday despite Washington’s backing, due to expected skepticism about a new draft, sources close to the talks told Reuters.

ECONOMIC IMPACT

* Global stocks again hit record highs and oil rose on Tuesday, before European and U.S. data that should this week offer major clues to the health of the world economy.

* Euro zone manufacturing activity expanded at a record pace in May, according to a survey which suggested growth would have been even faster without supply bottlenecks that have led to an unprecedented rise in input costs.

* Ireland will begin to gradually phase out temporary coronavirus-related jobless payments later this year while maintaining other income and business supports as the economy fully reopens, Public Expenditure Minister Michael McGrath said.

* Turkish factory activity shrank in May for the first time in a year as output and new orders slowed down due to a 17-day full lockdown imposed to curb a surge in new coronavirus cases, a survey showed.

(Compiled by Jagoda Darlak and Ramakrishnan M.; Editing by William Maclean)

India COVID-19 variant exhibits resistance; antibody drug shows promise

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

India variant shows resistance to antibody drugs, vaccines

Antibody drugs and COVID-19 vaccines are less effective against a coronavirus variant that was first detected in India, according to researchers. The variant, known as B.1.617.2, has mutations that make it more transmissible. It is now predominant in some parts of India and has spread to many other countries. A multicenter team of scientists in France studied a B.1.617.2 variant isolated from a traveler returning from India. Compared to the B.1.1.7 variant first identified in Britain, the India variant was more resistant to antibody drugs, although three currently approved drugs still remained effective against it, they found. Antibodies in blood from unvaccinated COVID-19 survivors and from people who received both doses of the Pfizer/BioNTech vaccine were 3-fold to 6-fold less potent against the India variant than against the UK variant and a variant first identified in South Africa, according to a report posted on Thursday on the website bioRxiv ahead of peer review. The two-dose AstraZeneca vaccine, which does not protect against the South Africa variant, is likely to be ineffective against the India variant as well. Antibodies from people who had received their first dose “barely inhibited” this India variant, said study co-author Olivier Schwartz of Institut Pasteur. The study, Schwartz added, shows that the rapid spread of the India variant is associated with its ability to “escape” the effect of neutralizing antibodies.

New antibody drug keeps mild COVID-19 from worsening

An antibody drug from Vir Biotechnology and GlaxoSmithKline that protects against progression of COVID-19 in high-risk patients with mild to moderate disease received emergency use authorization by the U.S. Food and Drug Administration on Wednesday. In a large randomized trial, patient risk of progression to more severe illness was reduced by 85% with the drug, sotrovimab, compared to a placebo, according to an interim report from the trial posted on Friday on the medRxiv website in advance of peer review. Everyone in the trial had risk factors for severe COVID-19 such as heart disease, diabetes, obesity and old age. Three of 291 patients (1%) in the sotrovimab group became sick enough to be hospitalized, versus 21 of 292 (7%) in the placebo group, researchers said. All five patients who needed to be admitted to intensive care received placebo, they reported. Serious complications were less common with sotrovimab than with placebo, they added. The antibody treatment will be available for COVID-19 patients in the coming weeks, GSK and Vir said on Wednesday.

Joint and muscle disease drugs may limit vaccine response

The COVID-19 vaccines from Pfizer/BioNTech and Moderna may be less effective in patients taking immunosuppressant drugs for rheumatic and musculoskeletal diseases, researchers said. “While additional research is required, patients on immunosuppressants should be aware that they may not be fully protected against COVID even after full vaccination. Therefore, patients should talk to their providers before relaxing precautions,” said Dr. Julie Paik of Johns Hopkins University School of Medicine in Baltimore. In an earlier study, her team found that most patients with rheumatic and musculoskeletal diseases do respond appropriately to the vaccines. Looking more closely at 20 people whose immune systems did not respond well – that is, no antibodies were detectable after vaccination – the researchers found that most were receiving multiple immunosuppressive agents. “A unifying factor” among the patients was their use of medications such as rituximab and mycophenolate mofetil that affect immune cells called lymphocytes that produce antibodies and help control immune responses, the researchers reported on Monday in the journal Annals of Internal Medicine. “Our study highlights the need for physicians and patients to be aware that immunosuppressants may prevent an appropriate vaccine response against SARS-CoV-2,” Paik said.

Robust, coordinated immune response marks mild COVID-19

In COVID-19 patients who do not become seriously ill, the immune system reacts to the virus “robustly,” with a highly coordinated response, and this coordination may be one key to ensuring a mild illness, according to researchers. Detailed studies of immune system behavior in COVID-19 patients have focused primarily on those with moderate or severe illness and have found “uncoordinated” immune responses. The new study, posted Wednesday on the bioRxiv website ahead of peer review, “used cutting-edge methods to deeply study immune cells” in 18 patients with only mild illness, said study co-author Greg Szeto of the Allen Institute for Immunology in Seattle. In these mildly ill volunteers, the more intense the immune response in early infection, the higher the levels of antibodies in their blood after recovery, the multicenter research team found. And compared to participants who recovered, participants who had lingering troublesome symptoms – so-called Long Covid – had weaker immune responses to the virus in early infection, Szeto added. The differences the study found between mildly ill patients who did and did not develop Long Covid may help researchers devise more personalized ways to monitor immune responses to the virus and better methods for treatment, Szeto’s team concluded.

 

(Reporting by Nancy Lapid and Megan Brooks; Editing by Will Dunham)

Cyclone leaves more than 150,000 people homeless in eastern India

By Subrata Nagchoudhury and Jatindra Dash

KOLKATA, India (Reuters) – More than 150,000 people were left homeless in the aftermath of a cyclone that unleashed storm surges in eastern India and Bangladesh, officials said on Thursday, with heavy rains hampering relief work in some low-lying coastal areas.

At least five people were killed in the two countries after Cyclone Yaas moved inland from the Bay of Bengal on Wednesday, packing gusts of up to 140 kph (87 mph) and whipping up tidal surges in India’s West Bengal state and neighboring Bangladesh.

Indian officials said the storm had weakened into a depression after hitting the coast but heavy rain poured down in parts of West Bengal, where there was fresh inundation of sea water along some coastal villages on Thursday.

“Restoration work will be difficult unless the weather improves,” West Bengal state minister Bankim Hazra told Reuters.

In West Bengal’s Sundarbans delta, which stretches into Bangladesh, at least 25,000 homes, many of them traditional mud houses, had been destroyed, leaving 150,000 people homeless, Hazra said, citing preliminary estimates.

The storm, the second to hit India in a week, arrived as the country grapples with a deadly second wave of coronavirus infections that has stretched the healthcare system to breaking point.

Some 500,000 people were sheltered in relief camps in West Bengal and officials said they had taken steps to reduce the risk of a potential spread of the virus.

“Flood shelters have quarantine rooms for those showing symptoms of COVID-19 like fever, sore throat, body ache,” Dr. Indranil Bargi, a medical officer in Gosaba area, told Reuters.

People are being tested for coronavirus using the rapid antigen test and anyone who tests positive would be shifted to safe homes set up in government offices and schools, he said.

Authorities in Bangladesh reported flooding of villages due to torrential rains and tidal surges. Three people were dead, two by drowning and a third who was hit by a tree, an official at the Disaster Management Agency said.

“I have never seen a tidal surge rising to this level. It flooded many villages and washed away houses. Many people are marooned,” said Humayum Kabir, an official in the coastal district of Khulna.

Elsewhere on the sub-continent, Nepal was bracing for floods in its plains and landslides in the hills as heavy rains have lashed the Himalayan country since Wednesday and were forecast to last till Saturday.

(Reporting by Jatindra Dash in Bhubaneshwar, Subrata Nagchoudhury in Kolkata, Ruma Paul in Dhaka and Gopal Sharma in Kathmandu; Writing by Sanjeev Miglani and Devjyot Ghoshal; Editing by Simon Cameron-Moore/Mark Heinrich)